Benitec Biopharma (BNTC) vs Indaptus Therapeutics (INDP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Benitec Biopharma (BNTC) has outperformed Indaptus Therapeutics (INDP) over the past year, losing 34.8% versus a loss of 38.8%. Over five years, BNTC leads with a -85.3% price change compared with -99.0% for INDP. Benitec Biopharma is the larger company by market cap ($313.6 million vs $301.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTC | INDP |
|---|---|---|
| Share price | $8.99 | $2.26 |
| Market cap | $313.60M | $301.13M |
| 1-day change | -0.11% | -12.74% |
| YTD return | -33.26% | -22.34% |
| 1-year return | -34.76% | -38.75% |
| 5-year return | -85.27% | -98.97% |
| EPS (TTM) | $-0.98 | $-6.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.76 | $5.96 |
| 52-week low | $8.52 | $0.92 |
| Distance from 52-week high | -46.36% | -62.08% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +170.63% | — |
| Average volume | 150.34K | 832.95K |
| Shares outstanding | 34.88M | 133.24M |
| Employees | 24 | 5 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Benitec Biopharma
BNTC stock →Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
Healthcare · Biotechnology · 24 employees
About Indaptus Therapeutics
INDP stock →Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.
Healthcare · Biotechnology · 5 employees
BNTC vs INDP FAQ
Which is bigger, Benitec Biopharma or Indaptus Therapeutics?
Benitec Biopharma (BNTC) is larger, with a market capitalization of $313.60M compared with $301.13M for Indaptus Therapeutics (INDP).
Which stock has performed better over the past year, BNTC or INDP?
BNTC returned -34.76% over the past 12 months, compared with -38.75% for INDP (price return, excluding dividends). Past performance does not predict future results.
Are Benitec Biopharma and Indaptus Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.